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region) in each country. Overall rates of OT/PT visits were reported. Patients who 
reported an OT/PT visit in the past six months were compared with those who did 
not with respect to demographics, health history, and comorbidity variables. Logistic 
regression models were then conducted to predict OT/PT visits from these varia-
bles. Results: Rates of OT/PT visits did not change from 2010 to 2013 but significant 
differences among countries was observed (p< .05). In 2013, France (0.54%) and the 
US (4.51%) had the most infrequent visits while Spain (11.13%) and Germany (11.92%) 
had the most frequent. Being in Germany (OR= 3.46), being in Spain (OR= 3.24), and 
having an above the median income (OR= 1.14) were the strongest demographic 
predictors of an OT/PT visit (all p< .05). Although most comorbidities were associated 
with an increased probability of an OT/PT visit, pain (OR= 2.30), arthritis conditions 
(OR= 1.73), and psychiatric conditions (OR= 1.73) were most strongly associated (all 
p< .05). ConClusions: PT and OT utilization varies significantly across countries, 
being highest in Germany and Spain where over 10% of adults reported a visit in the 
past six months. Pain-related (pain, arthritis) and psychiatric comorbidities were 
among the strongest predictors of PT/OT use.
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A Gender Medicine Post-Hoc AnAlysis: BAckGround And MetHods of 
tHe MetAGeM Project
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1Medidata srl, Modena, Italy, 2Novartis Farma Italy, Saronno (VA), Italy
objeCtives: Gender is a social construct, which is defined by the way people 
perceive themselves and how they expect others to behave. Gender medicine 
is the field of medicine that studies the biological and physiological differ-
ences between the human sexes and how that affects differences in disease. 
The progress of research has confirmed that men and women differ not only 
sexually but also in relationship to factors such as liver enzymes, sex hor-
mones and to variables determined by the environment, education, culture 
and psychology of the individual [Soldin and Mattison, 2009; Regitz-Zagrosek 
and Seeland 2012]. The Italian Drug Agency has recognized the importance of 
gender-specific analysis when evaluating new drug efficacy. The gender-medi-
cine METAGEM project aims to describe gender differences in clinical outcomes, 
therapeutic approach and safety parameters in real world data. Methods: 
Areas of interest were defined regarding Dermatology, Central nervous system, 
Infectivology, Rheumatology, and Transplantation; data were considered which 
were collected in ten observational studies conducted between 2002 and 2013 
in Italy in routine clinical practice. A post-hoc subgroup analysis is performed 
by study, during which males are compared with females by statistical tests. 
A merge of different study data will be performed in order to evaluate safety. 
As post-hoc analysis all p-values are exploratory. Results: The number of 
enrolled patients range between 238 to 1746 considering Rheumatology 
and Dermatology areas respectively, for a total of 3743 male and 3018 female 
patients. ConClusions: The papers and congress communications which will 
arise from METAGEM project will make the scientific community more aware of 
the importance of a gender-dedicated approach in the care of patients.
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HeAltH-econoMics in czecH rePuBlic: cAn forMAl HeAltH-econoMic 
MetHodoloGy iMProve tHe QuAlity of suBMitted AnAlysis?
Hambalek J., Spurna M., Vocelka M., Ballokova A.
State Institute for Drug Control, Prague, Czech Republic
objeCtives: Health economic analysis (HEA) has been required since 2008 as a 
part of drug reimbursement applications submitted to the State Institute for Drug 
Control (SUKL). In 2013, SUKL introduced a formal health economic guideline, mostly 
based on the Czech Pharmacoenomic Society´s guideline published in 2011. The 
aim of this study was to assess the impact of guideline implementation on the 
quality of submitted HEAs. Methods: We reviewed all (18) applications for new 
innovative drugs with prescription limited to specialized centers, in which the 
final decision was issued and came into force between 1/2013-6/2014. The HEAs 
were described in terms of type of analysis and further confronted with a ‘HEA 
checklist‘ to identify common deficiencies in submitted HEAs. All check-lists were 
peer-reviewed to ensure objectivity. Our results were compared with previously 
published research (assessing HEAs submitted in 2008-2009 before the guideline 
release). Results: All investigated dossiers contained HEA. Nine of them (50%) 
were cost-effectiveness analysis (outcome expressed mostly in LYGs) and nine (50%) 
were cost-utility analyses (outcome in QALYs). In general, the quality of HEAs was 
higher compared to the previous research, with ‘evidence completeness’ and ‘uncer-
tainty’ being the most commonly marked as ‘unsatisfactory’ in the HEA checklist 
(less than 50%). Our results showed that 1/3 HEAs fell into the ‘best’ category (80-
100% ‘satisfactory’ questions), while none of HEAs fell into this category in previous 
research. ConClusions: The present analysis showed a trend in higher quality of 
submitted analyses (1/2013-6/2014) compared with years 2008-2009.
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Price coMPArison in tHe euroPeAn PHArMAceuticAl MArket
Ressl S., Walter E.
Institute for Pharmaeconomic Research, Vienna, Austria
objeCtives: Due to rising health care costs, stricter governmental cost contain-
ment measures like international price comparison and external reference pricing, 
the European pharmaceutical markets will lead to future challenges in pricing. 
Despite of these prices of pharmaceuticals vary across European countries. Thus, 
the aim of the analysis was to draw a comprehensive picture of the pharmaceuti-
cal price levels and consumption (expenditure per capita) of pharmaceuticals in 
Europe. Methods: The study analyzed drug prices of the outpatient setting (Rx 
and OTC) of all countries of the European Union except Denmark plus Switzerland. 
Hungarian Forint / DRG costweight). ConClusions: Introduction of degressive 
financing method – in addition to DRG reimbursement – managed to control the 
activity of hospitals. The soft regulation in 2011 and 2012 resulted in a 4.2-4.6% 
excess activity of hospitals, while the more rigorous regulation in 2013 managed to 
decrease the excess hospital activity to 1.9%. Degressive regulation can serve as a 
cost containment tool for health policy decision makers.
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nuB stAtus - A 2014 situAtion AnAlysis for druGs: oncoloGy As 
leAdinG tHerAPeutic AreA
Friedmann B.1, Keck E.2, Schalk E.3, Schmitz D.2
1Quintiles Commercial, Mannheim, Germany, 2Healthcare Manufaktur, Cologne, Germany, 
3Quintiles, Mannheim, Germany
objeCtives: In the German hospital landscape NuB’s (Neue Untersuchungs- und 
Behandlungsmethoden) are essentially the precursor for cost-intensive drugs to 
be reimbursed within the G-DRG system. Hospitals can only start SHI negotiations 
for reimbursement once drugs have been given a NuB 1 status. The objective of 
this research was to provide an overview on the proportion of drugs (vs. methods, 
medicinal products) and their respective indications, which submitted NuB applica-
tions for 2014. Methods: The German DRG database issued by the InEK (Institute 
for the Hospital Remuneration System) was used to analyse NuB subgroups sorted 
according to key therapeutic indications. In parallel, the number of NuB 1 status 
products that went through the AMNOG process was analysed. Results: Out of 
618 NuB submissions, only 133 (22%) were classified as drugs. In total, 114 (18%) 
of all NuB applications received a NuB 1 status, out of these 43 (38%) were drugs. 
The leading therapeutic area of the NuB 1 status drugs was oncology with 28 drugs 
(65%), followed by 5 ophthalmic products (12%). NuB 2 status was given to 465 (75%) 
procedures out of which 82 (18%) were drugs. The analysis reveals that, the suc-
cess rate to receive the essential NuB 1 status is relatively low. Chances to receive 
a successfull NuB 1 status approval is one in three for drugs, however only one in 
six for other procedures. Out of the 43 drugs that were given NuB 1 status, already 
24 (55%) passed through the AMNOG process and were given equal proportions 
from important additional benefit to no additional benefit. ConClusions: Drug 
applications are more likely than procedures to be given NuB 1 status and thereby 
initiate reimbursement negotiations with the SHI. The application quality and sup-
port by the scientific societies and treatment centres is essential to make a NuB 
application successful.
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MulticriteriA decision AnAlysis And cost AnAlysis in HeAltH cAre 
decision MAkinG: A literAture review
Ivlev I., Landova M.
Czech Technical University in Prague, Kladno, Czech Republic
objeCtives: The purpose this literature review is to investigate the application of 
multicriteria decision analysis and cost analysis methods within health care deci-
sion-making. Methods: A search of the literature was conducted using scintific 
databases. A combination of the following key words and phrases were inputted 
into these databases: Analytic Hierarchy Process (AHP), Analytic Network Process 
(ANP), ELimination and Choice Expressing REality (ELECTRE), Goal programming, Grey 
relation analysis, Markov process, Technique for Order of Preference by Similarity 
to Ideal Solution (TOPSIS), CBA, CEA, and related words. The located articles were 
divided into the following twelve health care topics: evaluation of health informa-
tion services; evaluation of the product development process; project and technology 
selection; pharmaceutics; health care management; therapy/treatment; management 
of medical waste; human resource planning in health care; organ transplantation; 
evaluation of health care policy; diagnostics; and shared decision-making with the 
patient. Results: Ninety research articles were retrieved and determined relevant. 
The pertinent articles were published between 1981 and 2013. It was found that the 
AHP is the most commonly used method in health care decision making (65 articles). 
AHP is mainly exploited in project and technology selection (22). The ANP method 
is utilized in the evaluation of health information services, project and technology 
selection, pharmaceutics and therapy/treatment. For the evaluation of health care 
policy AHP (11), CBA (1), CEA (1) and Grey relation analysis (1) were used. The TOPSIS, 
VIKOR, Markov process methods were utilized once in human resource planning 
in health care, health care management and therapy/treatment respectively. The 
CBA (4) and CEA (2) methods were especially useful for solving therapy/treatment 
tasks. ConClusions: Multicriteria decision analysis and cost analysis offers a scien-
tifically sound evaluation framework for health care management, where stakeholder 
interests are of crucial concern and complex criteria that cannot easily be reduced to 
simple monetary expressions, can be assessed in resource limited settings.
PHP9
trends in PHysicAl And occuPAtionAl tHerAPy utilziAtion in tHe us 
And western euroPe
Eichmann F.1, DiBonaventura M.2, Schoefer A.3
1Kantar Health, Munich, Germany, 2Kantar Health, New York, NY, USA, 3Private Practice, 
Marquartstein, Germany
objeCtives: Allied health care (AHC) disciplines, such as physical (PT) and occupa-
tional therapy (OT), are primarily performed by non-medical health care profession-
als. Although the budget impact of AHC is generally low, reimbursements are often 
scrutinized for their financial impact and benefit/risk ratios. To better inform the 
health care decision making regarding AHC, the aim of this study was to examine 
trends and utilization of PT and OT. Methods: Data from the 2013 US (N= 75,000) 
and 2013 5EU (France, Germany, Italy, Spain, and UK; N= 62,000) National Health and 
Wellness Survey (NHWS). The NHWS is a patient-reported survey administered to 
a demographically representative sample of adults (with respect to age, sex, and 
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in the period September 2013 to June 2014. Quality was assessed using the criteria 
for pharmacoeconomic evaluations from the in the most recent ISPOR guidelines 
and the Serbian pharmacoeconomic guidelines. The impact of the introduction of 
the new rulebook was assessed by comparing the period following its introduction 
with the number and quality of submissions in the preceding period. Results: 
Between September 2013 and April 2014 there were 268 submissions to the NHIF and 
none were accompanied by the necessary pharmacoeconomic analysis. The new 
rulebook was published in April 2014, making budget impact analysis an obligatory 
part of every submission, and cost-effectiveness analysis obligatory for all new 
INNs. 127 new and renewal submissions were made between April and June 2014, 
47 for new INNs, 31 original and 16 for innovative medicines. All 47 completed the 
obligatory pharmacoeconomic analysis. There was a widespread failure to reach the 
requirements laid out in either the Guidelines for Pharmacoeconomic Evaluations 
for Serbia or ISPOR guidelines. ConClusions: The introduction of compulsory 
pharmacoeconomic component to reimbursement submissions in Serbia has raised 
the standard of submissions to the NHIF. This standard is still too low to fully facili-
tate transparent evidence based decision making, however the new rulebook is 
expected to force both the NHIF and the pharmaceutical industry to increase their 
skills in evidence based decision making. However, Serbia still suffers from a lack 
of the information required to construct quality pharmacoeconomic analysis, with 
limited local cost estimates available and limited supply of health economic skills 
in the region.
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Are Prices of PAtent-Protected PHArAMceuticAls in tHe toP 5 eu 
countries converGinG?
Reinaud F.1, Ando G.2
1IHS, Paris, France, 2IHS, London, UK
objeCtives: The goal of this study is to assess whether prices of innovative drugs 
in the top 5 EU markets converge over time. Methods: Price trends of a sample of 
50 innovative drugs, approved by the European Medicines Agency (EMA) in 2009 or 
earlier, that are still patent-protected and marketed in each of the top 5 EU markets 
were analysed over the period 2009-2014. The focus was on ex-manufacturing prices, 
which were extracted from IHS’s international pricing database POLI. Discounts and 
rebates were excluded from the analysis, and current exchange rates into Euros 
were used. Given the timeframe, none of the products included in the sample was 
assessed under the AMNOG reform in Germany. Results: While the data indicates 
that there are still price differences across countries in 2014, these differences have 
declined over time. In 2009, the price difference between the highest priced country 
(Germany) and the lowest one (United Kingdom) was 24%; this figure dropped down 
to 15% in 2014. The average price of the 50 products declined in all countries and 
the overall price mean (all countries) slightly decreased - by around 5% - over the 
period studied: from € 303.3 in 2009 to € 289.0 in 2014. This demonstrates a global 
trend leading innovative drug prices to decrease over time while they are still patent 
protected. ConClusions: Our data shows that prices slightly decrease over time, 
and also that prices have started to decline in Germany. German prices in the sample 
are still comparatively higher than the other major European markets, but with 
most prices in Italy and Spain remaining constant, and those in France converging 
to the mean, there are clear trends of price corridors shrinking across Europe. The 
divergence is commonly larger at launch, and converges over time.
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lettinG tHe dAtA sPeAk: A sHift of tHe PHArMAceuticAl sPendinG to 
HouseHolds in Greece
Kyriopoulos D.1, Ollandezos M.1, Papadopoulos K.1, Kyriopoulos I.I.2, Pentafragas V.1
1Pan Hellenic Union of Pharmaceutical Industry, Athens, Greece, 2National School of Public Health, 
Athens, Greece
objeCtives: Since 2009, Greece has implemented a fiscal consolidation pro-
gramme that includes several reforms and budget cuts in health sector. Indicatively, 
health expenditure has been reduced by more than 20% between 2009 and 2012. 
Pharmaceutical sector can be characterized as one of the main sources of these 
cuts. The objective of this study is to draw some early conclusions regarding the 
impact of the current pharmaceutical policy on the structure of expenditure and the 
access to medicines. Methods: The data are obtained from the Hellenic Statistical 
Authority, the national accounts and the household surveys for the period 2009-
2012, in order to examine potential changes of the public/private mix of the phar-
maceutical expenditure. Results: Public pharmaceutical expenditure fell from € 5.1 
bn in 2009 to € 3 bn in 2012 (-42.5%). Private pharmaceutical expenditure was € 1.3 bn 
in 2009, while it was approximately € 1.5 bn in 2012 (+12.4%). The total expenditure 
dropped by 31.2%. The share of private expenditure on pharmaceuticals has sharply 
increased during the study period. Specifically, the private expenditure was 20.6% 
of the total pharmaceutical expenditure in 2009, while it approximated 34% in 2012. 
ConClusions: The aforementioned imply that there is a shift from public to pri-
vate spending for pharmaceuticals between 2009 and 2012. Moreover, preliminary 
estimates for 2013 suggest that this trend is increasing. Therefore, apart from the 
existing financial and income constraints, households are in front of an additional 
financial burden. This change is associated with potential catastrophic expenditures 
and reduction in patient compliance. The study findings suggest that individuals’ 
degrees of freedom are constrained and that patients express their preferences by 
increased out of pocket payments. In the light of the above, the pharmaceutical 
policy implemented so far can be associated to a sharp “indirect increase” of copay-
ment and coinsurance rates. 
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econoMic Burden of intrAvenous iron Products in PuBlic HosPitAls 
of PAris And iMPAct of tHeir new HosPitAl-restricted stAtus
Therasse C.1, Bocquet F.2, Fusier I.1, Cordonnier A.L.1, Sinègre M.1
1General Agency of Equipment and Health Products (AGEPS), AP-HP, Paris, France, 2Dauphine 
University, Paris, France
Based on ex-factory prices per Standard Unit SU (tablet, vial etc.), price indices were 
calculated. Study results showed international pharmaceutical price levels (in Euro 
and purchasing power parities) and expenditure per capita. Observation period was 
the year 2012. Data were collected via international literature review and based on 
IMS Health data on file. Results: The international comparison of prices indices 
based on SU prices showed (European average price = 100), France (138) and UK (126) 
had the highest price indices and in contrast to Netherlands (69) and Romania (69) 
were at the lower end. In the international country sample, the Netherlands had the 
highest health expenditure (11.91% of GDP) in 2011, closely following by France with 
11.33% of GDP. Subsequently, Switzerland occupied a leading position based on the 
determined price index per capita (187) per ex-factory price, followed by Sweden 
(167). The rear was Romania (45). ConClusions: In case of converting drug prices 
with purchasing power parities differences between drug prices and affordability 
in different countries were found. Low income countries reported less affordability 
of drugs, leaving room for potential problems with drug access, and consequently, 
a negative impact on health.
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How is current PHArMAceuticAls PricinG Policy on Generics 
PerforMinG in turkey reGArdinG Price erosion?
Gürsoy K., Köselerli R., Dogru S.T., Köksal I.
Social Security Institution of Turkey, Ankara, Turkey
objeCtives: Generics are commonly accepted to contribute significantly to treating 
disease by improving the affordability of pharmaceuticals. Once the patent expires 
for an originator brand, generics erode prices through creating fierce competition. 
The objective of this study is to investigate on Turkish pharmaceutical policies over 
generics through measuring how much they lower the prices, and then develop 
alternative strategies to maintain higher level of price reduction and hence sav-
ing. Methods: Claims data from Turkish Social Security Institution for all ambula-
tory care drugs reimbursed were collected monthly in the period of January 2009 to 
December 2013. First, the share of generic drugs both in terms of sales volume and 
value were calculated. Then, selected 12 equivalent groups each relying on same 
molecule were evaluated and saving impacts due to generic entry were computed. 
Finally, the price erosion for 15 generics entering the reimbursement list in 2012 as 
first generics was measured. Results: Only 48% of all units sold was prescribed as 
generic drugs, whereas it was only 31% when it comes to value. For 12 equivalent 
groups constituting nearly 7% of SSI drug spending, the price erosion was nearly 
41% ranging from 8% to 74%. Interestingly, when a first generic having an origina-
tor brand whose any form were marketed before 1987 in any country entered the 
market, new discounted public price was higher than the price with no generic. 
Finally, in the first year of the first generic entry, on average the prices were only 
shrunk by 39% with an increase of 41% in units sold. ConClusions: Turkey is not 
maximizing its full potential with respect to generic medicines. Therefore, it is 
of great importance that policies such as therapeutic equivalence, tendering, and 
aggressive generic pricing policy to stimulate higher savings need to be introduced.
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cost-effectiveness of tArGeted PHArMAcotHerAPy – A systeMAtic 
review of tHe literAture
Amler N., Becker T., Bierbaum M., Schöffski O.
Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany
objeCtives: Targeted therapies (e.g. trastuzumab, cetuximab) are often said to 
constitute a new era of medicine. The new agents promise to be more effective 
and less toxic than standard care. The consequences on costs are still a matter of 
debate. While proponents refer to the enormous cost saving potential due to the 
avoidance of side effects or hospitalizations for example, opponents expect a mas-
sive increase in costs of care. However, the impact of targeted therapies on cost as 
well as their benefits are not yet clear. This review assesses the cost-effectiveness of 
targeted therapies. Methods: We searched Medline, the Cochrane Library, Scopus, 
ISI Web of Knowledge and ScienceDirect for relevant articles published between 2001 
and 2013. Internet search and scanning reference lists complemented our search. 
Authors independently reviewed titles, assessed articles’ eligibility for inclusion, 
determined methodological quality and extracted relevant data. Results: In total 
487 studies were identified. 50 of them met the inclusion criteria. 39 studies tar-
get either trastuzumab, or one of the aromatase inhibitors anastrozole, letrozole 
or exemestane. Quality of the studies was assessed using the checklist provided 
by Drummond/Jefferson (1996). The majority of the studies scored 80% or higher. 
With few exceptions studies are based on Markov models. Effectiveness as well as 
cost data were mostly obtained from clinical trials or literature respectively. Stated 
cost-effectiveness ratios ranged from 4.370€ /QALY to 220.658€ /QALY, whereas the 
majority of studies report favorable incremental cost-effectiveness ratios (≤ 50.000€ /
QALY). Models often did not incorporate the respective companion test adequately. 
Almost all studies were funded by the pharmaceutical industry. Studies without 
financial support report higher cost-effectiveness ratios. ConClusions: Results 
of the review indicate that targeted therapies seem to be cost-effective compared 
to standard care. As most of the studies have been funded by pharmaceutical com-
panies, authors suggest that results must be interpreted with care.
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iMPAct of PHArMAcoeconoMic Guidelines on tHe reiMBurseMent 
Process of Medicines in serBiA in 2014
Baltezarevic D.1, Novakovic T.1, Parker M.2, Samardzic J.3
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objeCtives: To assess the impact of new rules for pharmacoeconomic evaluations 
in Serbia, after the publishing of a new rulebook covering the criteria, methods and 
conditions for listing medicines for reimbursement. Methods: We investigated the 
reimbursement submissions to the National Health Insurance Fund (NHIF) in Serbia, 
